Oncomine Myeloid Assay Offers Comprehensive Testing for Myeloid Disorders
The Oncomine Myeloid Assay GX V2 is a next-generation sequencing (NGS) panel designed to analyze DNA mutations and RNA fusion transcripts associated with myeloid disorders. This test is particularly relevant for conditions such as acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and chronic myeloid leukemia (CML). The assay provides rapid and accurate results, with a turnaround time of three days. It profiles key genetic mutations and fusions, aiding in diagnosis, risk stratification, and evaluation for targeted therapies. The test is suitable for newly diagnosed patients and those requiring risk assessment or targeted treatment options. 
